甲磺酸伊马替尼治疗慢性粒细胞白血病的疗效观察(2)
 |
| 第1页 |
参见附件。
[3] Deininger M， O'Brien SG， Guilhot F. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up： sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [ J] . Blood，2009，114： 1126.
[4] Hughes TP， Hochhaus A， Branford S， et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia： an analysis from the International Randomized Study of Interferon and STI571 (IRIS)[J].Blood，2010，116： 3758-3765.
[5] Ganesan P， Sagar TG， Kannan K， et al. Upfront imatinib in pediatric chronic myeloid leukaemia yields results comparable to stem cell transplant[J].Blood，2011，118： 1607.
[6] Muramatsu H， Kojima S， Yoshimi A， et al.Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors： the Japan Marrow Donor Program[J].Biol Blood Marrow Transplant，2010，16： 231-238.
[7] Cwynarski K， Roberts IA， Iacobelli S， et al. Stem cell transplantation for chronic myeloid leukemia in children[J].Blood，2003，102： 1224-1231.
[8] Suttorp M， Yaniv I， Schultz KR. Controversies in the treatment of CML in children and adolescents： TKIs versus BMT[J].Biol Blood Marrow Transplant，2011，17：115-122.
编辑/申磊
您现在查看是摘要介绍页，详见PDF附件。